We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effectiveness Study of Different Local Anesthetic Mixtures (CA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01243112
Recruitment Status : Completed
First Posted : November 18, 2010
Results First Posted : December 2, 2011
Last Update Posted : December 2, 2011
Sponsor:
Information provided by (Responsible Party):
James Collins, Scott and White Hospital & Clinic

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Purpose and Background The purpose of this research study is to investigate the benefits of mixing lidocaine and bupivacaine for numbing the skin. Lidocaine and bupivacaine are two commonly used medications to numb the skin for minor procedures. Lidocaine has a faster onset. Bupivacaine has a longer duration. They are often combined with epinephrine to increase the length of action. These medications are used to control pain at the time of the operation and to decrease discomfort immediately afterward. Participating in the study involves injection of local anesthetic containing lidocaine, bupivacaine, and lidocaine and bupivacain with epinephrine at 4 sites on the forearm. Your participation will potentially improve the administration of these medications in persons undergoing a variety of procedures. You will be one of approximately 25 healthy volunteer subjects in this research study.

Condition or disease Intervention/treatment Phase
Pain Drug: 1% Lidocaine with Epinephrine (1:100,000) Drug: 0.25% Bupivacaine with Epinephrine (1:200,000) Drug: 0.5% Lidocaine, 0.125 Bupivacaine, and epi (1:150,000) Drug: 1% Lidocaine, 0.5% Bupivacaine, and epinephrine (1:150,000) Phase 4

Detailed Description:

Procedures

During your participation the following procedures will be completed:

  • You will be asked to read over and sign this consent form, if you choose to participate
  • You will be asked demographic information and your medical history will be obtained
  • If you are eligible to participate, the palm side of your forearm will be marked for the location of the treatments
  • Four small injections will be made into the palm side of your forearms with the local anesthetic mixtures (you will not know which injection is used at each of the four injection sites)
  • A small needle will be used for pinprick sensation to determine when numbness begins and ends

Length of Study and Number of Visits This study begins at the time the medications are injected and is completed when sensation has completely returned. The study will last between 6 and 12 hours. During this time, you may perform low intensity tasks including reading, typing, and writing. You must remain in the study location as the sites will frequently be examined.

Exclusions

You should not participate in this study if any of the following apply to you:

  • You are pregnant
  • You have an allergy to lidocaine or bupivacaine
  • You have a history of heart disease (including a prior heart attack, heart dysfunction, or heart failure)

There may be other criteria that you have to meet to be eligible for this study. The study team can discuss these with you to determine whether you qualify.

Discomfort and Risks Risks associated with the injections include temporary discomfort at the injection site and possible infection. It is also possible that you have an allergic reaction or side effect to the medications that are being used.

Benefits There is no direct benefit to you for participating in this study. Your participation will potentially improve the administration of these medications in persons undergoing a variety of procedures.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Onset and Duration of Effect of Lidocaine, Bupivacaine, and Lidocaine/Bupivacaine Mixture With Epinephrine.
Study Start Date : May 2010
Actual Primary Completion Date : September 2010
Actual Study Completion Date : September 2010

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Lidocaine w/ Epi
0.2ml 1% Lidocaine with Epinephrine (1:100,000)
 Drug: 1% Lidocaine with Epinephrine (1:100,000)
0.2ml Intradermal injection once.
Experimental: Bupivacaine with epi
0.2 ml 0.25% Bupivacaine with epinephrine (1:200,000)
 Drug: 0.25% Bupivacaine with Epinephrine (1:200,000)
0.2ml Intradermal injection once.
Experimental: Low dose Lido and Bupi w/ Epi
0.2ml 0.5% Lidocaine + 0.125% Bupivacaine with Epinephrine (1:150,000)
 Drug: 0.5% Lidocaine, 0.125 Bupivacaine, and epi (1:150,000)
0.2ml Intradermal injection once.
Experimental: High Dose Lido and Bupi with epi
0.2ml 1% Lidocaine + 0.25% Bupivacaine with Epinephrine (1:150,000)
 Drug: 1% Lidocaine, 0.5% Bupivacaine, and epinephrine (1:150,000)
0.2ml Intradermal injection once.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Length of Action [ Time Frame: Up to 12 hours ]
    The time from onset of local anesthesia until cessation of effect by sensation of sharp measured in 15 minute increments.

  2. Onset of Action [ Time Frame: Up to 5 minutes ]
    Time from infusion of local anesthetic to loss of sensation to sharp.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age: 18-60

Exclusion Criteria:

  • Pregnancy
  • allergy to local anesthetics
  • history of heart disease or diabetes
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01243112


Locations
Layout table for location information
United States, Texas
Scott & White
Temple, Texas, United States, 76504
Sponsors and Collaborators
Scott and White Hospital & Clinic
Investigators
Layout table for investigator information
Principal Investigator: James B Collins, MD Scott and White Healthcare
Study Director: Raman C Mahabir, MD Scott and White Healthcare
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: James Collins, MD, Scott and White Hospital & Clinic
ClinicalTrials.gov Identifier: NCT01243112    
Other Study ID Numbers: 090520
First Posted: November 18, 2010    Key Record Dates
Results First Posted: December 2, 2011
Last Update Posted: December 2, 2011
Last Verified: October 2011
Additional relevant MeSH terms:
Layout table for MeSH terms
Lidocaine
Epinephrine
Racepinephrine
Bupivacaine
Epinephryl borate
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Anti-Arrhythmia Agents
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
 Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Adrenergic beta-Agonists
Bronchodilator Agents
Autonomic Agents
Anti-Asthmatic Agents
Respiratory System Agents
Mydriatics
Sympathomimetics
Vasoconstrictor Agents